Melatonin and diabetes: from pathophysiology to the treatment perspectives
https://doi.org/10.14341/2072-0351-3751
Abstract
Pineal hormone melatonin synchronizes insulin secretion and glucose homeostasis with solar periods. Misalliance between melatonin-mediated circadian rhythms and insulin secretion characterizes diabetes mellitus type 1 (T1DM) and type 2 (T2DM). Insulin deficiency in T1DM is accompanied by increased melatonin production. Conversely, T2DM is characterized by diminished melatonin secretion. In genome-wide association studies the variants of melatonin receptor MT2 gene (rs1387153 and rs10830963) were associated with fasting glucose, beta-cell function and T2DM. In experimental models of diabetes melatonin enhanced beta-cell proliferation and neogenesis, improved insulin resistance and alleviated oxidative stress in retina and kidneys. However, further investigation is required to assess the therapeutic value of melatonin in diabetic patients.
About the Authors
Vladimir Iosifovich Konenkov
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
akademik RAMN, d.m.n., prof., direktor
akademik RAMN, d.m.n., prof., direktor
Vadim Valerievich Klimontov
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
d.m.n., zav. laboratoriey endokrinologii
d.m.n., zav. laboratoriey endokrinologii
Svetlana Viktorovna Michurina
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
d.m.n., professor, g.n.s. laboratorii funktsional'noy morfologii limfaticheskoy sistemy
d.m.n., professor, g.n.s. laboratorii funktsional'noy morfologii limfaticheskoy sistemy
M A Prudnikova
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
m.n.s. laboratorii endokrinologii
m.n.s. laboratorii endokrinologii
I Ju Ishenko
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
k.b.n., s.n.s. laboratorii funktsional'noy morfologii limfaticheskoy sistemy
k.b.n., s.n.s. laboratorii funktsional'noy morfologii limfaticheskoy sistemy
References
1. Borjigin J, Zhang LS, Calinescu AA. Circadian regula- tion of pineal gland rhythmicity. Mol Cell Endocrinol. 2012;349(1):13–9.
2. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev. 2003;55(2):325–95.
3. Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. Scientific World Journal 2012:640389.
4. Slominski RM, Reiter RJ, Schlabritz–Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351(2):152–66.
5. Анисимов В.Н. Эпифиз, биоритмы и старение организма. Успехи физиологических наук 2008;39(4):40–65.
6. Арушанян Э.Б., Попов А.В. Современные представления о роли супрахиазматических ядер гипоталамуса в организации суточного периодизма физиологически функций. Успехи физиологических наук 2011;42(4):39–58.
7. Бородин Ю.И., Труфакин В.А., Мичурина С.В., Шурлыгина А.В. Структурно-временная организация печени, лимфатической, иммунной, эндокринной систем при нарушении светового режима и введении мелатонина. Новосибирск: Издательский дом «Манускрипт»,2012:208.
8. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009;106(11):4453–8.
9. Bailey CJ, Atkins TW, Matty AJ. Melatonin inhibition of insulin secretion in the rat and mouse. Horm Res. 1974;5(1):21–8.
10. Mühlbauer E, Peschke E. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res. 2007;42(1): 105–6.
11. Nagorny CL, Sathanoori R, Voss U, Mulder H, Wierup N. Distribution of melatonin receptors in murine pancreatic islets. J Pineal Res. 2011;50(4):412–7.
12. Ramracheya RD, Muller DS, Squires PE, Brereton H, Sugden D, Huang GC, Amiel SA, Jones PM, Persaud SJ. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res. 2008;44(3):273–9.
13. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spégel P, Bugliani M, Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, Mulder H, Groop L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8.
14. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, Sparsø T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Roche- leau G, Durand E, De Graeve F, Chèvre JC, Borch-Johnsen K, Hartikainen AL, Ruokonen A, Tichet J, Marre M, Weill J., Heude B, Tauber M, Lemaire K, Schuit F, Elliott P, Jørgensen T, Charpentier G, Hadjadj S, Cauchi S, Vaxillaire M, Sladek R, Visvikis-Siest S, Balkau B, Lévy-Marchal C, Pattou F, Meyre D, Blakemore AI, Jarvelin MR, Walley AJ, Hansen T, Dina C, Ped- ersen O, Froguel P. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.
15. Mühlbauer E, Albrecht E, Hofmann K, Bazwinsky-Wutschke I, Peschke E. Melatonin inhibits insulin secretion in rat insulinoma β-cells (INS-1) heterologously expressing the human melatonin receptor isoform MT2. J Pineal Res. 2011;51(3):361–72.
16. Frankel BJ, Strandberg MJ. Insulin release from isolated mouse islets in vitro: no effect of physiological levels of melatonin or arginine vasotocin. J Pineal Res. 1991;11(3–4):145–8.
17. Peschke E, Wolgast S, Bazwinsky I, PГnicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res. 2008;45(4): 439–48.
18. Nogueira TC, Lellis-Santos C, Jesus DS, Taneda M, Rodrigues SC, Amaral FG, Lopes AM, Cipolla-Neto J, Bordin S, Anhê GF. Absence of melatonin induces night-time hepatic insulin resistance and increased gluconeogenesis due to stimulation of nocturnal unfolded protein response. Endocrinology 2011;152(4):1253–63.
19. la Fleur SE, Kalsbeek A, Wortel J, van der Vliet J, Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night-time glucose concentrations. J Neuroendocrinol. 2001;13(12):1025–32.
20. Picinato MC, Haber EP, Carpinelli AR, Cipolla-Neto J. Daily rhythm of glucose-induced insulin secretion by isolated islets from intact and pinealectomized rat. J Pineal Res. 2002;33(3):172–7.
21. Nishida S, Sato R, Murai I, Nakagawa S. Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. J Pineal Res. 2003;35(4):251–6.
22. Ferreira DS, Amaral FG, Mesquita CC, Barbosa AP, Lellis–Santos C, Turati AO, Santos LR, Sollon CS, Gomes PR, Faria JA, Cipolla-Neto J, Bordin S, Anhê GF. Maternal melatonin programs the daily pattern of energy metabolism in adult offspring. PLoS One 2012;7(6):e38795.
23. Шатило ВБ, Бондаренко ЕВ, Антонюк-Щеглова ИА. Метаболические нарушения у пожилых больных с гипертонической болезнью и их коррекция мелатонином. Успехи геронтол. 2012;25(1):84–89.
24. Prokopenko I, Langenberg C, Florez JC, Saxena R, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81.
25. Kelliny C., Ekelund U., Andersen L.B., Brage S., Loos R.J., Wareham N.J., Langenberg C. Common genetic determinants of glucose homeostasis in healthy children: the European Youth Heart Study. Diabetes 2009; 58 (12): 2939–45.
26. Reiling E, van 't Riet E, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, Maassen JA, Dekker JM, 't Hart LM. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia 2009;52(9):1866–70.
27. Peschke E, Hofmann K, Bähr I, Streck S, Albrecht E, Wedekind D, Mühlbauer E. The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia 2011;54(7):1831–40.
28. Simsek N, Kaya M, Kara A, Can I, Karadeniz A, Kalkan Y. Effects of melatonin on islet neogenesis and beta cell apoptosis in streptozotocin-induced diabetic rats: an immunohistochemical study. Domest Anim Endocrinol. 2012;43(1):47–57.
29. Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, Spessert R, Mühlbauer E. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40(2):135–43.
30. Mäntele S, Otway DT, Middleton B, Bretschneider S, Wright J, Robertson MD, Skene DJ, Johnston JD. Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men. PLoS One 2012;7(5):e37123.
31. Джериева И.С., Рапопорт С.И., Волкова Н.И. Связь между содержанием инсулина, лептина и мелатонина у больных с метаболическим синдромом. Клиническая медицина 2011;6:46–9.
32. Гриненко Т.Н., Баллюзек М.Ф., Кветная Т.В. Мелатонин как маркер выраженности структурно-функциональных изменений сердца и сосудов при метаболическом синдроме. Клиническая медицина 2012;2:30–4.
33. Robeva R, Kirilov G, Tomova A, Kumanov Ph. Melatonin–insulin interactions in patients with metabolic syndrome. J. Pineal Res. 2008;44(1):52–56.
34. do Carmo Buonfiglio D, Peliciari-Garcia RA, do Amaral FG, Peres R, Nogueira TC, Afeche SC, Cipolla-Neto J. Early-stage retinal melatonin synthesis impairment in streptozotocin- induced diabetic wistar rats. Invest. Ophthalmol Vis Sci. 2011;52(10):7416–22.
35. Hikichi T, Tateda N, Miura T. Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin. Ophthalmol. 2011;5:655–660. doi: 1 http://dx.doi.org/0.2147/OPTH.S19559.
36. Kanter M, Uysal H, Karaca T, Sagmanligil HO. Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats. Arch Toxicol. 2006;80(6):362–9.
37. de Oliveira AC, Andreotti S, Farias Tda S, Torres-Leal FL, de Proença AR, Campaña AB, de Souza AH, Sertié RA, Carpinelli AR, Cipolla-Neto J, Lima FB. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZ-induced diabetic rats are improved by long-term melatonin treatment. Endocrinology 2012;153(5):2178–88.
38. Anwar MM, Meki AR. Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol. 2003;135(4):539–47.
39. Lin GJ, Huang SH, Chen YW, Hueng DY, Chien MW, Chia WT, Chang DM, Sytwu HK. Melatonin prolongs islet graft survival in diabetic NOD mice. J Pineal Res. 2009;47(3):284–92.
40. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernández- Vázquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. 2012;52(2):203–10.
41. Agil A, Reiter RJ, Jiménez-Aranda A, Ibán-Arias R, Navarro- Alarcón M, Marchal JA, Adem A, Fernández-Vázquez G. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J Pineal Res. 2012 In press. doi: http://dx.doi.org/10.1111/jpi.12012.
42. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf). 2012 Jun;205(2):209–223. doi: http://dx.doi.org/10.1111/ j.1748-1716.2012.02410.x.
43. Koziróg M, Poliwczak AR, Duchnowicz P, Koter- Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011Apr;50(3):261–266. doi: http://dx.doi.org/10.1111/j.1600-079X.2010.00835.x.
44. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307–13.
45. Baydas G, Tuzcu M, Yasar A, Baydas B. Early changes in glial reactivity and lipid peroxidation in diabetic rat retina: effects of melatonin. Acta Diabetol. 2004;41(3):123–8.
46. Salido EM, Bordone M, De Laurentiis A, Chianelli M, Keller Sarmiento MI, Dorfman D, Rosenstein RE. Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res. 2012. doi: http://dx.doi.org/10.1111/jpi.12008.
47. Ha H, Yu MR, Kim KH. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic. Biol. Med. 1999;26(7–8):944–50.
48. Oktem F, Ozguner F, Yilmaz HR, Uz E, Dindar B. Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol. 2006;33(1–2):95–101.
49. Dayoub JC, Ortiz F, López LC, Venegas C, Del Pino-Zumaquero A, Roda O, Sánchez-Montesinos I, Acuña-Castroviejo D,Escames G. Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide. J Pineal Res. 2011;51(3):324–30.
50. Reyes-Toso CF, Linares LM, Ricci CR, Obaya-Naredo D, Pinto JE, Rodríguez RR, Cardinali DP. Melatonin restores endothelium-dependent relaxation in aortic rings of pancreatectomized rats. J Pineal Res. 2005;39(4):386–91.
51. Qiu XF, Li XX, Chen Y, Lin HC, Yu W, Wang R, Dai YT. Mo- bilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats. Asian J Androl. 2012;14(3):481–6.
52. Коненков В.И., Климонтов В.В. Ангиогенез и васкулоге- нез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений. Сахарный диабет 2012;4:17–27.
53. Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. Blood pressure response to melatonin in type 1 diabetes. Blood pressure response to melatonin in type 1 diabetes. Pediatr. Diabetes 2004;5(1):26–31.
54. Бондарь И.А., Климонтов В.В., Королева Е.А., Желтова Л.И. Суточная динамика артериального давления у больных сахарным диабетом типа 1 с нефропатией. Проблемы эндокринологии 2003; 49(5):5–10.
Review
For citations:
Konenkov V.I., Klimontov V.V., Michurina S.V., Prudnikova M.A., Ishenko I.J. Melatonin and diabetes: from pathophysiology to the treatment perspectives. Diabetes mellitus. 2013;16(2):11-16. (In Russ.) https://doi.org/10.14341/2072-0351-3751
Views:
22245
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
